Free Trial

Neos Therapeutics (NEOS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
15.01 million shs
Average Volume
7.44 million shs
Market Capitalization
$57.22 million
P/E Ratio
Dividend Yield
Price Target
NEOS stock logo

About Neos Therapeutics Stock (NASDAQ:NEOS)

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

NEOS Stock News Headlines

Cara Therapeutics, Inc. (CARA)
Kiss of death from Joe Biden
I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.
Presidio Partners 2007 GP, L.P.'s Net Worth
Kiss of death from Joe Biden
I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.
See More Headlines
Receive NEOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings

Industry, Sector and Symbol

Pharmaceutical Preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$64.65 million
Book Value
($0.12) per share


Free Float
Market Cap
$57.22 million
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Gerald W. McLaughlin (Age 53)
    CEO, Pres & Director
    Comp: $561.95k
  • Mr. Richard I. Eisenstadt (Age 63)
    CFO, Treasurer & Corp. Sec.
    Comp: $387.59k
  • Ms. Margaret Cabano
    VP of Operations
  • Mr. John P. Limongelli (Age 51)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Joe Calarco
    Chief Compliance Officer
  • Ms. Sarah Foster
    VP of HR
  • Mr. Russ McMahen
    Sr. VP of R&D

NEOS Stock Analysis - Frequently Asked Questions

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics, Inc. (NASDAQ:NEOS) released its earnings results on Monday, November, 9th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.05. The business earned $12.54 million during the quarter.

What is Mark Tengler's approval rating as Neos Therapeutics' CEO?

10 employees have rated Neos Therapeutics Chief Executive Officer Mark Tengler on Mark Tengler has an approval rating of 26% among the company's employees. This puts Mark Tengler in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did Neos Therapeutics IPO?

Neos Therapeutics (NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What other stocks do shareholders of Neos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neos Therapeutics investors own include Verastem (VSTM), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL) and Rigel Pharmaceuticals (RIGL).

This page (NASDAQ:NEOS) was last updated on 7/13/2024 by Staff

From Our Partners